David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Feb

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Colorectal Cancer How Does Lifetime Alcohol Consumption Affect Risk

New Report Shows Colorectal Cancer is Now Leading Cancer Death Among Those Under 50

Can Color Vision Deficiency Impact Survival in Bladder or Colorectal Cancer

Cancer Surgery Outcomes Similar Between Rural and Urban Facilities

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma